Dr Luc-André Granier, MD, PhD : CEO

25 years of experience in big pharma, biotech and CROs, an extensive experience in managing high risk programs of Novel Chemical Entities (NCE) in Central Nervous System.

Dr. Granier  was a former member of FORENAP a well known French CRO specialising in clinical development of CNS drugs performing clinical services for pharmaceutical & biotechnology companies. Dr Granier was head of the clinical development unit managing and running clinical trials from phase I to phase III in Neurosciences. He was then Senior Clinical Research Physician/Clinical Neuropsychopharmacologist at Eli Lilly & Co. He has run with success the proof of concept study for duloxetine (Cymbalta, Xeristar, Yentreve), approved by the FDA in autumn 2004. Dr Granier joined Synt:em in 2001 as Vice President, Clinical Development and Medical Director where he was in charge of the general clinical development strategy for the company. 

 In the last 20 years Dr Granier has been in charge and strongly involved in developing various exciting new program in Neurosciences, including development of neurokinin antagonist (NK 1, NK 2 and NK 3), metabotropic and ionotropic Glutamate receptor agonist and antagonist (kaynate and NMDA antagonist, group 1 metabotropic glutamate antagonist, group 2 metabotropic glutamate agonist and antagonist) and serotonin receptor agonist and antagonist.

Dr. Granier received his M.D. and his PhDs. from the University Louis Pasteur of Strasbourg, France.

Mrs Caroline Roussel-Maupetit : COO

13 years of experience in Biotech - Extensive experience in project management, sub-contracting early clinical projects and contract manufacturing.

Mrs Roussel was the co-founder of Synt:em a French biotech company where she held the position of Vice-President, Director of Operations. She was mainly in charge of the pharmaceutical development of candidate drugs in pre clinical/clinical development in the field of acute pain, neuropathic pain and oncology.

Mrs. Roussel was trained as an engineer in industrial biology from the University of Compiègne and graduated from the European Institute for Entrepreneurial Management school in Montpellier.  In 1993, she was sales manager at Protéine Performance interfacing between researchers and partners from industry and academia for recombinant protein expression projects.  In addition, she has strong marketing and sales experience with a variety of biotechnology products.  From 1995 to 1999, she acted as Marketing Director for Synt:em in particular she was in charge of the custom peptide business unit, setting up the facilities and was strongly involved in research and development project coordination.